LifeWatch and BioTelemetry: Enrollment Choices That Changed the Monitoring Service

In the LifeWatch 2023 enrollment settlement, BioTelemetry and LifeWatch agreed to pay $14,734,628 over allegations that their enrollment process put patients into more expensive cardiac monitoring than physicians ordered or medical necessity supported. The government alleged that clinic staff selected telemetry through the company’s portal even when doctors wanted event monitoring, and that LifeWatch disregarded notes spelling out the intended service. The physician’s instruction was there. The company allegedly provided and billed for something more expensive anyway. Taxpayers funded the difference.

The Department of Justice announced the settlement on December 18, 2023. LifeWatch Services was BioTelemetry’s subsidiary, and one of the whistleblowers worked for a LifeWatch customer. Whistleblowers brought two cases, and the government agreed to join them for settlement. Someone on the ordering side of the business could see the gap between what the clinic requested and what the supplier did.

The Cardiac Monitor and the Service Billed

LifeWatch marketed its ACT-3L device as capable of Holter monitoring, cardiac event monitoring and mobile cardiovascular telemetry. The settlement agreement also identifies the device as LifeStar ACT-3L and MCT-3L. One product could support different services with different reimbursement.

BioTelemetry and LifeWatch operated independent diagnostic testing facilities that performed the technical components of those services. In the agreement’s account, Holter monitoring had the lowest federal reimbursement and telemetry the highest. The financial incentive sat in the service selected for the patient, even though the device could perform all three.

The billing codes made that choice concrete. LifeWatch used CPT 93226 for Holter monitoring, CPT 93271 for event monitoring and CPT 93229 for telemetry. The government’s allegations covered claims billed under the telemetry code instead of the event-monitoring code from July 1, 2014, through December 31, 2020.

That is why a product name alone tells too little about the bill. A clinic could intend to use the device for event monitoring while the supplier enrolled the patient in telemetry. The enrollment selection connected the physician’s order to a more expensive technical service.

LifeWatch Monitoring Enrollment Portal Choices and MCOT

Mobile cardiac outpatient telemetry, or MCOT, continuously transmits cardiac data to a remote diagnostic center. The government alleged that LifeWatch Connect steered clinical staff toward telemetry through two choices, MCT and Holter + MCT. The agreement describes how each route could depart from what the physician intended.

MCT was also called the ACT service. It enrolled the patient directly in telemetry. Holter + MCT was also called ACT Ex, a sequential service in which the issue arose after a non-diagnostic Holter test. The government alleged that patients entered the higher-paying service even when the physician intended a less expensive one, either from the start or after that initial Holter test.

The allegation reached beyond the interface. According to the United States, sales personnel told clinic staff to select MCT or Holter + MCT even when the company knew the physicians intended event monitoring for many or all patients. LifeWatch then allegedly provided and billed for telemetry.

Written instructions should have made the intended service especially clear. The government alleged that account personnel included notes specifically requesting event monitoring, but LifeWatch disregarded them. It also alleged that the company did not consistently follow accounts’ instructions about enrollment handling after those issues were brought to its attention.

For a clinic employee, those notes may be the most recognizable part of the case. The allegation was that the supplier had been told what the doctors wanted and still delivered the higher-paying service. A portal selection, a sales instruction and a written correction can tell different stories about the same enrollment.

What the Settlement Covered

The signed agreement allocated $12,936,574 to ACT enrollments and $1,798,054 to ACT Ex enrollments. The split followed the two enrollment paths and the two whistleblower actions, one in New Jersey and the other in Eastern Pennsylvania.

Those distinctions matter because ACT and ACT Ex reached telemetry differently. One began there. The other paired Holter monitoring with a later service. Keeping the paths separate makes it possible to compare each enrollment with the physician’s instruction at the relevant point, including what was intended after a non-diagnostic Holter test.

Which Federal Programs Paid for the Cardiac Monitoring?

The federal payers identified in this cardiac-monitoring case were Medicare, TRICARE, the Federal Employees Health Benefits Program and the Department of Veterans Affairs. The government alleged that LifeWatch submitted the disputed claims to those programs.

What Evidence Is Needed to Report Fraud?

In an enrollment case like LifeWatch’s, we trace the mismatch between the physician’s order and the bill. The portal choice, enrollment notes and service records help us establish where the decisions diverged and what the supplier knew.

A clinic employee may know the physician’s instruction and the message sent with the enrollment. A sales employee may know what staff were told to select. A monitoring or billing employee may see the service actually provided and the code submitted for payment. Each view helps explain a different decision inside the same transaction.

Other LifeWatch and BioTelemetry Monitoring Settlements

LifeWatch’s 2012 monitoring settlement concerned alleged false diagnostic codes and referral inducements.

In a 2015 settlement involving BioTelemetry and CardioNet, the government likewise alleged inaccurate diagnostic codes that represented a greater medical need for MCOT. The later LifeWatch enrollment case concerned whether the supplier honored the physician’s chosen service.

BioTelemetry’s Offshore ECG Technicians and Medicare Settlement

The separate BioTelemetry and CardioNet settlement announced in 2022 concerned allegations that federal beneficiaries’ ECG data went to technicians in India, and that technicians lacked required credentials. That case followed the work after the patient entered monitoring.

How Much Is a Whistleblower Claim Worth?

In the LifeWatch enrollment settlement, the Justice Department announced an approximately $2.3 million reward for the whistleblower employed by a customer. The agreement separately allocated a share to SFP I, LLC, which brought the Eastern Pennsylvania action. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

The customer employee’s role is especially relevant here. The mismatch could be visible at the clinic placing the order, outside the company billing for the service. We work with insiders on either side of that transaction to connect what they saw to the claims and the company’s decisions.

You Know What the Physician Ordered

If you saw enrollment choices, sales instructions or ignored notes turn a physician’s order into a more expensive monitoring bill, speak with our whistleblower experts. We build the case with you and bring in remote cardiac-monitoring whistleblower lawyers who understand the connection between the order, the technical service and the claim. We stay beside you from the first call through the pursuit of the recovery.